211 
Universal Biosensors gets New $4.5M Technology Feasibility Project
Universal Biosensors, Inc. (ASX code: UBI) today announced that it has commenced a new research and development project for LifeScan affiliate, Cilag GmbH International. After undertaking some preliminary scoping work earlier in the year, Universal Biosensors will undertake a new research and development proje… Read all
|
Alchemia's cancer product shrinks lung tumors Phase II trial - preliminary data
Alchemia's lead cancer product from its HyACT technology, HA-Irinotecan was featured on Channel & News at 6 pm September 27 in most regions and also featured on Seven's Sunrise program on September 28.
The first two Small Cell Lung Cancer patients who received HA-Irinotecan have responded ve… Read all |
Sunshine Heart results show positive efficacy trend and strong safety profile
Sunshine Heart, Inc. (ASX: SHC), today announced Ohio State’s release of early results of a six month feasibility study utilizing Sunshine Heart’s minimally invasive C-Pulse system for Class III and ambulatory Class IV heart failure. Patients with moderate to severe heart failure, who were enrolled in a feasibil… Read all
|
Orbis Investment Management Ltd bought QRxPharma Ltd shares
Orbis Investment Management Ltd bought a net 3,175,331 QRxPharma Ltd shares between April 8 and September 16, 2011, increasing from 9,785,634 shares (7.78%) to 12,960,965 shares (8.99%).
Source: News Bites
|
Antisense - New Stem Cell Mobilization Indication - International Patent Application Lodged
Antisense Therapeutics (“ANP” or “the Company”) has advised of a potential new application for the Company’s drug ATL1102 as a stem cell mobilization agent in stem cell transplantation based on data generated from previously conducted studies on ATL1102. This data has formed the basis of an International Paten… Read all
|
Universal Biosensors Advances Point-of-Care Molecular Diagnostic Opportunity
Universal Biosensors, Inc. (ASX: UBI) today announced that it has signed a non-exclusive licence agreement with Australian company, SpeeDx Pty Ltd, for access to its proprietary MNAzyme technology. The SpeeDx technology is a sensitive and highly selective method for detecting sequences of DNA or RNA. he … Read all
|
Terms & Rules
As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use